Praluent (alirocumab)

pCPA File Number: 20949
Negotiation Status:
Concluded with an LOI
Indication(s):
Primary hypercholesterolemia (non-familial and heterozygous familial)
Sponsor/Manufacturer:
Sanofi-aventis Canada Inc.
CADTH Project Number:
SR0469-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: